Abstract:Following the approval of the first antibody-drug conjugates (ADCs) in the early 2000s, development has increased dramatically, with 14 ADCs now approved and >100 in clinical development. In lung cancer, trastuzumab deruxtecan (T-DXd) is approved in human epidermal growth factor receptor 2 (HER2)-mutated, unresectable or metastatic non-small-cell lung cancer, with ADCs targeting HER3 (patritumab deruxtecan), trophoblast cell-surface antigen 2 [datopotamab deruxtecan and sacituzumab govitecan (SG)] and mesenchymal-epithelial transition factor (telisotuzumab vedotin) in late-stage clinical development. In breast cancer, several agents are already approved and widely used, including trastuzumab emtansine, T-DXd and SG, and multiple late-stage trials are ongoing. Thus, in the coming years, we are likely to see significant changes to treatment algorithms. As the number of available ADCs increases, biomarkers (of response and resistance) to better select patients are urgently needed. Biopsy sample collection at the time of treatment selection and incorporation of translational research into clinical trial designs are therefore critical. Biopsy samples taken peri- and post-ADC treatment combined with functional genomics screens could provide insights into response/resistance mechanisms as well as the impact of ADCs on tumour biology and the tumour microenvironment, which could improve understanding of the mechanisms underlying these complex molecules. Many ADCs are undergoing evaluation as combination therapy, but a high bar should be set to progress clinical evaluation of any ADC-based combination, particularly considering the high cost and potential toxicity implications. Efforts to optimise ADC dosing/duration, sequencing and the potential for ADC rechallenge are also important, especially considering sustainability aspects. The ETOP IBCSG Partners Foundation are driving strong collaborations in this field and promoting the generation/sharing of databases, repositories and registries to enable greater access to data. This will allow the most important research questions to be identified and prioritised, which will ultimately accelerate progress and help to improve patient outcomes.

Radiation therapy, tissue radiosensitization, and potential synergism in the era of novel Antibody-Drug Conjugates

Synergizing Immunotherapy and Antibody–Drug Conjugates: New Horizons in Breast Cancer Therapy

Activity of antibody-drug conjugates (ADCs) with radiation in preclinical bladder cancer models.

Antibody-drug conjugates in solid tumors: a look into novel targets

Antibody–Drug Conjugates—Evolution and Perspectives

Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation

Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies

The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads

Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2

Antibody-Drug Conjugates: The New Frontier of Chemotherapy

Antibody-Drug Conjugates in Breast Cancer: Current Status and Future Directions

Unveiling the future of breast cancer therapy: Cutting-edge antibody-drug conjugate strategies and clinical outcomes

Spotlight on Ideal Target Antigens and Resistance in Antibody-Drug Conjugates: Strategies for Competitive Advancement

Targeting cancer with antibody-drug conjugates: Promises and challenges

A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy

Optimizing the safety of antibody–drug conjugates for patients with solid tumours

Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles

Potential of antibody–drug conjugates (ADCs) for cancer therapy

The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors

'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review

Unlocking the potential of antibody–drug conjugates for cancer therapy